Free Trial Information
BioCentury | Feb 24, 2014
Company News

Cuban Center for Genetic Engineering and Biotechnology (CIGB), Truffle Capital infectious, cancer news

...treat infectious diseases and cancer. Truffle merged three companies financed by Truffle - Splicos S.A.S., Wittycell S.A.S....
Read More
BioCentury | Jan 26, 2012
Targets & Mechanisms

Unleashing NK cells

...effects similar to those caused by blocking NCR1. Vincent Serra, CEO, CSO and cofounder of Wittycell S.A.S....
...Marseille, France Institut National de la Santé et de la Recherche Médicale , Marseille, France Wittycell S.A.S....
Read More
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

...compared with control treatment. Next steps include identifying other serum proteins with NK cell-stimulating activity. Wittycell S.A.S....
Read More
BioCentury | Jun 12, 2008
Distillery Techniques

This Week in Techniques

...a-GalCer stimulates antibody responses to pathogen-derived antigens and designing next-generation glycolipids to improve iNKT recruitment. Wittycell S.A.S....
Read More
BioCentury | Jun 12, 2008
Tools & Techniques

Primeless B Cell Boosting

...antigen to the NKT agonist can improve B cell response," said Vincent Serra, CEO of Wittycell S.A.S....
...Geneva , Geneva, Switzerland Weatherall Institute of Molecular Medicine , University of Oxford, Oxford, U.K. Wittycell S.A.S....
Read More
BioCentury | Apr 23, 2007
Emerging Company Profile

Wittycell: Outwitting the immune response

...adjuvants that can boost the immune response against a chosen antigen are becoming more important. Wittycell S.A.S....
Read More
BioCentury | Apr 23, 2007
Emerging Company Profile

Corporate Profile

Wittycell S.A.S. Paris, France Technology: Adjuvants for prophylactic and therapeutic vaccines based on natural killer T cell stimulation Disease focus: None Clinical status: NA Founded: 2005 by Jacky Bernard, Vincent Serra and Philippe Pouletty University...
Read More
BioCentury | Jan 8, 2007
Company News

Wittycell, Brigham Young University, Scripps Research Institute, University of Chicago deal

...Scripps obtained equity in Wittycell and are eligible for milestones. Further terms were not disclosed. Wittycell S.A.S....
Read More
Items per page:
1 - 8 of 8
BioCentury | Feb 24, 2014
Company News

Cuban Center for Genetic Engineering and Biotechnology (CIGB), Truffle Capital infectious, cancer news

...treat infectious diseases and cancer. Truffle merged three companies financed by Truffle - Splicos S.A.S., Wittycell S.A.S....
Read More
BioCentury | Jan 26, 2012
Targets & Mechanisms

Unleashing NK cells

...effects similar to those caused by blocking NCR1. Vincent Serra, CEO, CSO and cofounder of Wittycell S.A.S....
...Marseille, France Institut National de la Santé et de la Recherche Médicale , Marseille, France Wittycell S.A.S....
Read More
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

...compared with control treatment. Next steps include identifying other serum proteins with NK cell-stimulating activity. Wittycell S.A.S....
Read More
BioCentury | Jun 12, 2008
Distillery Techniques

This Week in Techniques

...a-GalCer stimulates antibody responses to pathogen-derived antigens and designing next-generation glycolipids to improve iNKT recruitment. Wittycell S.A.S....
Read More
BioCentury | Jun 12, 2008
Tools & Techniques

Primeless B Cell Boosting

...antigen to the NKT agonist can improve B cell response," said Vincent Serra, CEO of Wittycell S.A.S....
...Geneva , Geneva, Switzerland Weatherall Institute of Molecular Medicine , University of Oxford, Oxford, U.K. Wittycell S.A.S....
Read More
BioCentury | Apr 23, 2007
Emerging Company Profile

Wittycell: Outwitting the immune response

...adjuvants that can boost the immune response against a chosen antigen are becoming more important. Wittycell S.A.S....
Read More
BioCentury | Apr 23, 2007
Emerging Company Profile

Corporate Profile

Wittycell S.A.S. Paris, France Technology: Adjuvants for prophylactic and therapeutic vaccines based on natural killer T cell stimulation Disease focus: None Clinical status: NA Founded: 2005 by Jacky Bernard, Vincent Serra and Philippe Pouletty University...
Read More
BioCentury | Jan 8, 2007
Company News

Wittycell, Brigham Young University, Scripps Research Institute, University of Chicago deal

...Scripps obtained equity in Wittycell and are eligible for milestones. Further terms were not disclosed. Wittycell S.A.S....
Read More
Items per page:
1 - 8 of 8